Genmab (GMAB) and AbbVie (ABBV) announced the FDA granted priority review for the supplemental Biologics License Application, or sBLA, for epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GMAB:
- U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
- Transactions in connection with share buy-back program
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
- Genmab upgraded to Outperform from Market Perform at BMO Capital